<SEC-DOCUMENT>0001193125-14-375040.txt : 20141017
<SEC-HEADER>0001193125-14-375040.hdr.sgml : 20141017
<ACCEPTANCE-DATETIME>20141017161406
ACCESSION NUMBER:		0001193125-14-375040
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20141017
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20141017
DATE AS OF CHANGE:		20141017

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MYRIAD GENETICS INC
		CENTRAL INDEX KEY:			0000899923
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		IRS NUMBER:				870494517
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-26642
		FILM NUMBER:		141162061

	BUSINESS ADDRESS:	
		STREET 1:		320 WAKARA WAY
		CITY:			SALT LAKE CITY
		STATE:			UT
		ZIP:			84108

	MAIL ADDRESS:	
		STREET 1:		320 WAKARA WAY
		CITY:			SALT LAKE CITY
		STATE:			UT
		ZIP:			84108
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d807029d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 8-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant
to Section&nbsp;13 or 15(d) of the Securities Exchange Act of 1934 </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (Date of earliest event reported):
October&nbsp;17, 2014 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>MYRIAD GENETICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant as specified in its charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>0-26642</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>87-0494517</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>of&nbsp;incorporation)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(IRS Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>320 Wakara Way </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Salt Lake City, Utah 84108 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive offices) (Zip Code) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Registrant&#146;s telephone number, including area code: (801)&nbsp;584-3600 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Not Applicable </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Former
name or former address, if changed since last report) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<I>see </I>General Instruction A.2. below): </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>ITEM&nbsp;2.02</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Results of Operations and Financial Condition. </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October&nbsp;17, 2014, Myriad
Genetics, Inc. (&#147;Myriad&#148; or the &#147;Company&#148;) issued a press release announcing that it had received draft Medicare coverage for its Prolaris diagnostic test and also announcing selected preliminary financial information for the
Company&#146;s first fiscal quarter ended September&nbsp;30, 2014. The press release is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K, and the portions of the press release related to the Company&#146;s preliminary financial
results are incorporated herein by reference and are being furnished pursuant to this Item&nbsp;2.02. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has not completed its
financial close process for the quarter. During the course of that process, the Company may identify items that would require it to make adjustments, which may be material, to the selected preliminary financial information presented in the press
release. As a result, the preliminary financial estimates included in the press release constitute forward-looking information and are subject to risks and uncertainties, including possible adjustments to preliminary operating results. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In accordance with General Instruction B-2 of Form 8-K, the information set forth in Item&nbsp;2.02 and in Exhibit 99.1 related to the
Company&#146;s preliminary financial results shall not be deemed to be &#147;filed&#148; for purposes of Section&nbsp;18 of the Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;), or otherwise subject to the liability of that
section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended or the Exchange Act, except as shall be expressly set forth by specific reference in such
filing. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>ITEM&nbsp;8.01</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Other Events. </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In its press release issued on October&nbsp;17, 2014, the Company
announced that Palmetto GBA, a Medicare Administrative Contractor (MAC) that assesses molecular diagnostic technologies, has issued a draft local coverage determination (LCD) for Prolaris, Myriad&#146;s novel molecular diagnostic test that
accurately predicts cancer-specific death and metastases in men with prostate cancer. The LCD is posted to the Medicare Coverage Database on the Centers for Medicare &amp; Medicaid Services (CMS) website and establishes the coverage policy for
Medicare beneficiaries. The current language in the draft LCD provides reimbursement coverage for the estimated 50% of prostate cancer patients defined as low and very low risk. Under Medicare rules, the draft LCD is subject to a minimum 45-day
public comment period. After comments are considered, a final LCD is issued, which goes into effect after a minimum 45-day notification period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The press release is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K, and the portions of the press release related to the
Company&#146;s announcement of draft Medicare coverage for Prolaris are incorporated herein by reference and are being filed pursuant to this Item&nbsp;8.01.</P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>ITEM&nbsp;9.01</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Financial Statements and Exhibits. </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Exhibit</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; width:26.20pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Number</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1.00pt solid #000000; width:37.25pt; font-size:8pt; font-family:Times New Roman">Description</P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP ALIGN="center">99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press release dated October&nbsp;17, 2014, announcing draft Medicare coverage for Prolaris and selected preliminary first fiscal quarter financial information.</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The press release contains hypertext links to information on our websites or other parties&#146; websites. The
information on our websites and other parties&#146; websites is not incorporated by reference into this Current Report on Form 8-K and does not constitute a part of this Form 8-K. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"><B>MYRIAD GENETICS, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: October&nbsp;17, 2014</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Peter D. Meldrum</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">Peter D. Meldrum</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">President and Chief Executive Officer</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 4 </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d807029dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g807029g42r14.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="right">News Release </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="11%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="38%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="36%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Media&nbsp;Contact:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">Ron Rogers</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">Investor&nbsp;Contact:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">Scott Gleason</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">(801) 584-3065</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">(801) 584-1143</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><U>rrogers@myriad.com</U></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><U>sgleason@myriad.com</U></TD></TR>
</TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Myriad Receives Draft Medicare Coverage for
Prolaris<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Company Pre-Releases First Quarter Revenue and EPS; Confirms FY15
Guidance </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SALT LAKE CITY, Utah,&nbsp;Oct.&nbsp;17,&nbsp;2014</B>&nbsp;&#150;&nbsp;Myriad Genetics, Inc. (Nasdaq: MYGN) today&nbsp;announced
that&nbsp;Palmetto GBA, a Medicare&nbsp;Administrative&nbsp;Contractor (MAC) that assesses molecular diagnostic technologies, has issued a&nbsp;draft local&nbsp;coverage&nbsp;determination (LCD) for Prolaris, Myriad&#146;s revolutionary prostate
cancer test. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The LCD is&nbsp;posted to&nbsp;the Medicare Coverage Database on the Centers for Medicare&nbsp;&amp; Medicaid Services
(CMS)&nbsp;website&nbsp;and establishes the coverage policy&nbsp;for Medicare beneficiaries. The current language in the draft LCD provides reimbursement coverage for the approximately 50% of prostate cancer patients defined as low and very low
risk. Under Medicare rules, the draft&nbsp;LCD&nbsp;is subject to a minimum 45-day public comment period. After comments are considered, a final LCD is issued, which&nbsp;goes into effect after a minimum 45-day notification period.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;We are very excited by this draft coverage determination as a first step in ensuring that all Medicare prostate cancer patients will
have access to Prolaris testing which we believe provides the highest quality and most accurate assessment of their cancer&#146;s aggressiveness,&#148; said Pete Meldrum, president and CEO of Myriad. &#147;Prolaris is the only test that can use the
initial biopsy to accurately predict cancer-specific death in men with prostate cancer. In multiple clinical validation studies, Prolaris has been shown to be a much stronger indicator of clinical outcomes than adverse pathology for patients across
all risk categories.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>National Launch of Myriad myRisk&#153; Hereditary Cancer Test; Impact on Fiscal First Quarter Financial Results </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Myriad also announced today that the Company has initiated a national launch for its myRisk Hereditary Cancer test and sample volumes have
rapidly increased, exceeding Company expectations. myRisk sample volumes now represent more than 50 percent of all </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
hereditary cancer samples received by Myriad. With a more rapid transition to myRisk and higher than anticipated physician demand, the Company experienced an increase in costs to perform the test
and an increase in turnaround time during the first fiscal quarter ended September&nbsp;30, 2014. This increased turnaround time translated into increased work-in-progress, or WIP, and a corresponding decrease in revenue that was not anticipated
when Myriad issued its fiscal year 2015 financial guidance in August 2014. The Company now estimates first quarter revenue to be approximately $168 million and adjusted earnings per share to be approximately $0.25 (GAAP earnings per share of $0.21).
These estimates are based upon the Company&#146;s current projections and are subject to change. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company is responding to address its
customers&#146; needs and is hiring additional staff, as well as purchasing more equipment to meet this increased demand for myRisk testing. Myriad believes capacity will increase throughout the second fiscal quarter, and that it will be able to
reduce turnaround times beginning in the second half of fiscal year 2015.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While first quarter revenue was negatively impacted by
turnaround times, given the underlying strength of the business, the Company is reaffirming its financial guidance for the 2015 fiscal year of total revenues of $800 to $820 million and adjusted, fully diluted earnings per share of $1.90 to $2.00
(GAAP earnings per share of $1.75 to $1.85). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;We are very pleased with the high level of physician interest in myRisk, and we are
working hard to meet this demand,&#148; said Meldrum. &#147;We believe that our rapid conversion of the hereditary cancer market to gene panel testing, and the investments we have made in our new product pipeline, position Myriad exceptionally well
for the future.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Prolaris</B><SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> <B> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prolaris is a novel 46-gene RNA-expression test that directly measures tumor cell growth characteristics for stratifying the risk of disease
progression in prostate cancer patients. Prolaris provides a quantitative measure of the RNA expression levels of genes involved in the progression of tumor growth. Low gene expression is associated with a low risk of disease progression in men who
may be candidates for active surveillance and high gene expression is associated with a higher risk of disease progression in patients who may benefit from additional therapy. Prolaris has been proven to predict prostate cancer-specific disease
progression in 11 clinical trials with more than 6,000 patients. For more information visit: <U>www.prolaris.com</U>. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Myriad myRisk&#153;
Hereditary Cancer Testing </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Myriad myRisk Hereditary Cancer test uses next-generation sequencing technology to evaluate 25
clinically significant genes associated with eight hereditary cancer sites including: breast, colon, ovarian, endometrial, pancreatic, prostate and gastric cancers and melanoma. For more information visit:
<U><FONT STYLE="white-space:nowrap">www.myriad.com/products-services/hereditary-cancers/myrisk-hereditary-cancer/</FONT></U>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Myriad Genetics </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Myriad Genetics is a leading molecular diagnostic company dedicated to making a difference in patients&#146; lives through the discovery and
commercialization of transformative tests to assess a person&#146;s risk of developing disease, guide treatment decisions and assess risk of disease progression and recurrence. Myriad&#146;s molecular diagnostic tests are based on an understanding
of the role genes play in human disease and were developed with a commitment to improving an individual&#146;s decision making process for monitoring and treating disease. Myriad is focused on strategic directives to introduce new products,
including companion diagnostics, as well as expanding internationally. For more information on how Myriad is making a difference, please visit the Company&#146;s website: www.myriad.com. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Myriad, the Myriad logo, BART, BRAC<I>Analysis</I>, Colaris, Colaris AP, myPath, myRisk, myRisk Hereditary Cancer, myChoice, myPlan,
BRACAnalysis CDx, HRD, Vectra and Prolaris are trademarks or registered trademarks of Myriad Genetics, Inc. in the United States and foreign countries. MYGN-F, MYGN-G </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note Regarding Preliminary Financial Results </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of the date of this release, the Company has not completed its financial close process for the quarter. During the course of that process,
the Company may identify items that would require it to make adjustments, which may be material, to the information presented above. As a result, the estimates included in the press release constitute forward-looking information and are subject to
risks and uncertainties, including possible adjustments to preliminary operating results. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Safe Harbor Statement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This press release contains &#147;forward-looking statements&#148; within the meaning of the Private Securities Litigation Reform Act of 1995,
including statements relating to the CMS draft local coverage determination for the Prolaris test, and the scope, timing and effectiveness of a final local coverage determination; the effectiveness of Prolaris testing being the only test to
accurately predict clinical outcomes or influence treatment plans for patients; the national launch for myRisk testing and continued increase in sample volumes; the continued volume of hereditary cancer testing being above Company projections; the
more rapid transition to myRisk, the higher than anticipated physician demand, and the increased cost to perform testing; increased turnaround times, increased work-in-progress and unanticipated corresponding revenue decreases for the myRisk test;
the Company&#146;s preliminary first quarter revenue and earnings per share estimates and reaffirmation of the financial guidance for fiscal year 2015; the Company&#146;s response to address its customers&#146; needs and the Company&#146;s belief
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
that capacity will increase throughout the second fiscal quarter and that the Company will be able to reduce WIP beginning in the second half of fiscal year 2015; the Company&#146;s beliefs that
it is exceptionally well positioned for the future; and the Company&#146;s strategic directives under the caption &#147;About Myriad Genetics.&#148; These &#147;forward-looking statements&#148; are based on management&#146;s current expectations of
future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by forward-looking statements. These risks and uncertainties include, but are
not limited to: the risk that sales and profit margins of our existing molecular diagnostic tests and pharmaceutical and clinical services may decline or will not continue to increase at historical rates; risks related to our ability to transition
from our existing product portfolio to our new tests; risks related to changes in the governmental or private insurers reimbursement levels for our tests or our ability to obtain reimbursement for our new tests at comparable levels to our existing
tests; risks related to increased competition and the development of new competing tests and services; the risk that we may be unable to develop or achieve commercial success for additional molecular diagnostic tests and pharmaceutical and clinical
services in a timely manner, or at all; the risk that we may not successfully develop new markets for our molecular diagnostic tests and pharmaceutical and clinical services, including our ability to successfully generate revenue outside the United
States; the risk that we may not be successful in transitioning from our existing product portfolio to our new products, such as our myRisk Hereditary Cancer test, which represents the next generation of our existing hereditary cancer franchise; the
risk that we may not be able to generate sufficient revenue from our existing tests and our new tests or develop new tests; the risk that licenses to the technology underlying our molecular diagnostic tests and pharmaceutical and clinical services
and any future tests are terminated or cannot be maintained on satisfactory terms; risks related to delays or other problems with manufacturing our products or operating our laboratory testing facilities; risks related to public concern over genetic
testing in general or our tests in particular; risks related to regulatory requirements or enforcement in the United States and foreign countries and changes in the structure of the healthcare system or healthcare payment systems; risks related to
our ability to obtain new corporate collaborations or licenses and acquire new technologies or businesses on satisfactory terms, if at all; risks related to our ability to successfully integrate and derive benefits from any technologies or
businesses that we license or acquire; risks related to increased competition and the development of new competing tests and services; risks related to our projections about the potential market opportunity for our products; the risk that we or our
licensors may be unable to protect or that third parties will infringe the proprietary technologies underlying our tests; the risk of patent infringement claims or challenges to the validity of our patents; risks related to changes in intellectual
property laws covering our molecular diagnostic tests and pharmaceutical and clinical services and patents or enforcement in the United States and foreign countries, such as </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the Supreme Court decision in the lawsuit brought against us by the Association for Molecular Pathology et al; risks of new, changing and competitive technologies and regulations in the United
States and internationally; and other factors discussed under the heading &#147;Risk Factors&#148; contained in Item&nbsp;1A in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, as well as any updates to
those risk factors filed from time to time in our Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. All information in this press release is as of the date of the release, and Myriad undertakes no duty to update this information unless
required by law. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Statement regarding use of non-GAAP financial measures </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In this press release, the Company&#146;s earnings per share guidance is provided in accordance with accounting principles generally accepted
in the United States (GAAP) and using non-GAAP or adjusted principles. The Company&#146;s earnings per share guidance under GAAP includes recurring amortization charges resulting from the acquisition of intangible assets including developed
technology and database rights that will be recognized over the useful lives of the assets. Management believes that presentation of its earnings per share guidance that excludes these items provides useful supplemental information to investors and
facilitates the analysis of the Company&#146;s core earnings and comparison of earnings across reporting periods. Management also uses non-GAAP financial measures to establish budgets and to manage the Company&#146;s business. A reconciliation of
the GAAP earnings per share guidance to non-GAAP earnings per share guidance is included below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company encourages investors to
carefully consider its results under GAAP, as well as its supplemental non-GAAP information and the reconciliation between these presentations, to more fully understand its business. Non-GAAP results are reported in addition to, and not as a
substitute for, or superior to, financial measures calculated in accordance with GAAP. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s future performance and
financial results are subject to risks and uncertainties, and actual results could differ materially from guidance set forth below. Some of the factors that could affect the Company&#146;s financial results are stated in the safe harbor statement of
this press release. More information on potential factors that could affect the Company&#146;s financial results are included under the heading &#147;Risk Factors&#148; contained in Item&nbsp;1A in the Company&#146;s most recent Annual Report on
Form 10-K filed with the Securities and Exchange Commission, as well as any updates to those risk factors filed from time to time in the Company&#146;s Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="94%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="4"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Reconciliation of GAAP to Non-GAAP Results for the First Quarter FY15</B></P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>&nbsp;&nbsp;</B></P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:1pt"></P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>1Q15</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Diluted net income per share</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">GAAP diluted net income per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;0.21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Acquisition - amortization of intangible assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.04</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Non-GAAP diluted net income per share</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B> 0.25</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Reconciliation of GAAP to Non-GAAP Fiscal Year 2015 Financial Guidance </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="88%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>Fiscal&nbsp;Year&nbsp;2015</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Diluted net income per share</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">GAAP diluted net income per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">$&nbsp;1.75&nbsp;&#150;$1.85</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Acquisition &#150; amortization of intangible assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">0.15</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Non-GAAP diluted net income per share</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><B>$&nbsp;1.90&nbsp;&#150;$2.00</B></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g807029g42r14.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g807029g42r14.jpg
M_]C_X``02D9)1@`!``$`8`!@``#__@`?3$5!1"!496-H;F]L;V=I97,@26YC
M+B!6,2XP,0#_VP"$``@&!@<&!0@'!P<*"0@*#18.#0P,#1L3%!`6(!PB(1\<
M'QXC*#,K(R8P)AX?+#TM,#4V.3HY(BL_0SXX0S,X.3<!"0H*#0L-&@X.&C<D
M'R0W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W
M-S<W-S<W-__$`:(```$%`0$!`0$!```````````!`@,$!08'"`D*"P$``P$!
M`0$!`0$!`0````````$"`P0%!@<("0H+$``"`0,#`@0#!04$!````7T!`@,`
M!!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I
M*C0U-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'
MB(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7
MV-G:X>+CY.7FY^CIZO'R\_3U]O?X^?H1``(!`@0$`P0'!00$``$"=P`!`@,1
M!`4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)B<H
M*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H*#A(6&
MAXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76
MU]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_``!$(`(@`M`,!$0`"$0$#$0'_V@`,
M`P$``A$#$0`_`/9/%FL7&A>'YK^U2-Y490!("5Y..Q%=&&I1JU%"1R8RO+#T
M74CN>=CXK:V/O6=@?HC_`/Q5>K_9M+N_Z^1X7]L5^R_'_,E7XL:F!\UA:GZ;
MA_6E_9M/^9E?VS5_E7XCQ\6;\==-MS]&:E_9L/YF/^V:G\J'CXM78ZZ7#_W\
M-+^S(_S#_MF?\B^\GMOBG>7,RPQ:/$SMT'G[?YBIEET8J[E^!<<XG)V4/Q-6
M/QMK#_\`,OQ'Z7R5B\)27V_P9TK,*S_Y=_\`DR+*>+=8;_F75/TOXJAX6FOM
M_@S18VL_^7?_`),BPGB35W_YET#_`+?XO\:AT*:^W^#-%BJS_P"7?_DR+":W
MJS?\P#'_`&^Q'^M3[&FOM_@RUB*W_/O\42#5M7/30A^-XE3[*G_/^#*]M6_Y
M]_BA3J6MX^705/\`V^+_`(4>SI?S_@'M:_\`S[_%$9U3Q`.GAL'_`+?4_P`*
M?LZ/\_X"]MB/^?7_`),B)M8\1KT\,`_]OR?X52I4/^?GX,AU\2O^77_DR('\
M0>)$_P"95'_@='5*A0_Y^?@R7B<2O^77_DR('\3^)$Z^%U'UO4JEAZ'_`#\_
M!F;Q>)7_`"Z_%$+>+_$*=?#<8_[>U/\`2K6%H_\`/S\"'CL2O^77XHHWGQ$U
M6PC$EQH<4:DXSY^>?P%:1P-.>D9_@8SS2M35Y4[?,H'XM77;2H?^_AK3^S(_
MS&/]LS_D7WC3\6;WMID`_P"!FG_9L/YF']LU/Y$=3X+\6W/B=KP3VT4(@"XV
M$\YSZ_2N+%X:.'M9WN>C@,;+%<W,K6.MKA/3"@#E/B-_R)=U_OI_Z$*[<!_'
M1YN:?[L_D>(5]$?(A0`4`%`!TH`4,01G)'IF@+(W+*6QO)?*AT/S7QG'VEA6
M$N>*NY_@=4/9R=E3O\V:T>F1M_S*6[_M^(_K6#J?]//P.F-%?\^?_)BW%HR]
MO!.?^XB1_6LW5_Z>_@;*A_TX_P#)BY%HY[>!3_X,S_C6;J_]/?\`R4U5#_IQ
M_P"3?\$N1:._;P*1_P!Q+_Z]9NK_`-/?P-E0?_/C_P`F+:Z.Q&#X+*C_`+"(
M_P`:CVO_`$]_`T]@_P#GQ_Y,(_AZ$CGP:Q/MJ'_V5"KM?\O?P$\,O^?/_DW_
M``2I+X<A/3P/*?IJ7_UZM5W_`,_?P,WA5_SX_P#)O^"5)/#2=O`D_P#X,O\`
MZ]:+$/\`Y^_@9/"+_H'?_@17?PXP^[X'N!_W$,U:Q'_3U?<9O"?].'_X$59?
M#\H_YDZ=?K>D_P!*M5U_S]7W&3PK7_+A_P#@10NM!N#"ZQ>')H7(X;[1NQ^%
M:QK1OK/\#&>'G;2DU\SG[S3[JP95NH6B+=,]ZZ(SC/X6<DZ<Z?Q*QZ'\)/O:
MK](__9J\O,_L_,]O)=Y_+]3TZO'/H0H`Y3XC?\B7=?[Z?^A"NW`?QT>;FG^[
M/Y'B%?1'R(4`%`!0`4`%`!TH`Z2QM(KNW66+P]-.IXW+<$9/Y5S3FXNSG;Y'
M93IJ2NJ3?S-&+1@W_,H7+?\`;X1_2L75_P"GJ^XZ%0_Z<O\`\"+<>A`]?!-T
M?^W\C^E9NM_T]7W&JP__`$X?_@1;CT)1_P`R/>#_`+B)J'6_Z>K[C58?_IP_
M_`BU'HP'_,E78_[B7_V59NK_`-/5]QJJ'_3A_P#@7_!+4>D#&/\`A$+M?^XC
M_P#95#J_]/%]W_`-51_Z<O\`\"_X(/H\9'/A74#]-1_^SH55_P#/Q?=_P!.@
MO^?3_P#`O^"5)-$C/_,HZD?^XA_]E6BK/_GXON_X!D\.O^?,O_`O^"5I-!C/
M_,G:A_X'5:K/_GZON,GAU_SXE_X$5I-`3MX-U#_P,_\`L:T5;_IZON,WAE_S
MXE_X$4I="Q_S*&H#_MY)_P#9*M5O^GJ^XR>'_P"G,OO_`.`4+G1I/+81^&[R
M-R."TQ.#]-M:1JKK47W&,J#MI2:^?_`.G^$RLDNK(P(9?+!!['YJXLRU43TL
MF5G-/R_4]-KR#Z`*`.4^(W_(EW7^^G_H0KMP'\='FYI_NS^1XA7T1\B%`!0`
M4`%`!0`4`;VG:5(]LC2:'>7.[D/&Y4$=N-IKGG42=E-(ZZ=%M7=-O^O0U(M$
M!Z^%-1/_`&\?_85BZW_3Q?=_P3H6'_Z<R^__`(!>BT-1U\(:G_X%8_\`9:S=
M;_I['[C58?\`Z<2^\M1Z*G_0HZF/^WW']*AUO^GL?N-%AU_SYE_X$6DT9!_S
M*>IC_M_Q_P"S5#J_]/%]W_`-507_`#YE_P"!?\$LQZ4J]/"VJ#_N(_\`V=9N
MI_T\7W?\`U5%?\^I?^!?\$D;3T`_Y%O61_NW_P#]LI<[_GC]W_`*]DO^?4O_
M``+_`()6?34_Z%S6_P#P-)_]FJU4?_/R/W?\`R=)?\^I_P#@7_!*TFF1G_F6
MM:/_`&]$UHJC_P"?D?N,G17_`#ZG_P"!?\$J2:2G;POK7_@1_P#8U:JO_GY'
M[C)T%_SYG]Y2FTF,?\RQK(^LW_V%:*J_^?D?N_X)DZ"_Y]3^_P#X!GSZ=#&K
M,?#^J(`,DM+T_P#'*T51O[:^[_@F4J45O3E]_P#P#I_A.5,VKE`53]W@$Y('
MS5Q9EM&YZ.36O.WE^IZ97D'T`4`<I\1O^1+NO]]/_0A7;@/XZ/-S3_=G\CQ"
MOHCY$*`"@`H`*`"@#4L]%OVE1Y=*O)82,XC0@GTYP:QE5@E925SHA0J-W<&T
M;46B'C_BG-7/TDQ_[)6#K?WX_P!?,Z5A_P#IU+[_`/@%V+1%'7PSK?\`W^Q_
M[)4.M_T\C]QJL.O^?4_O_P"`6X]&C'_,M:V/^WC_`.M4.J_^?D?N-%07_/J?
MWEJ/28Q_S+FM_P#@4*S=5_\`/R/W&BH+_GU/[_\`@EE-+C'_`#+VN?\`@9_]
MG4.H_P">/W?\`V5%?\^Y_P#@7_!)19PH,?V#X@'^[=D_^U*CG?\`/'[O^`7[
M.*_Y=S^__@C)((^@T;Q-CVN3_P#%U2;_`)H_=_P"7%?R3^__`()5>V3_`*`W
MB<_]MR?ZU:D_YX?<9."_Y]U/O_X)5DM$_P"@)XE_[^G_``K13?\`/#[C)TU_
MS[J?>4Y;6+_H"^(Q]9/_`+"M%)_SQ^XR<%_S[G]__`,^YBMHD9WTO6XT49+/
M)@`?]\5I%R>BE'[O^"8RC%*[A/[_`/@&%>W-K(JBT%RG][S90V1^`%=$5)?%
M8Y)R@_@O\V=]\)/O:K](_P#V:O,S/[/S/:R7>?R_4].KQSZ$*`.4^(W_`")=
MU_OI_P"A"NW`?QT>;FG^[/Y'B%?1'R(4`%`$D%O-<RB*")Y9#T5%)/Y"DVHJ
M[*C%R=HJY>7P]K#_`'=+NS_VQ;_"L_;4E]I&OU:L_L/[C8@\,L57S-!U@MCG
M:0!_Z!6#KKI./]?,Z8X5]:<OZ^1H1>'@N/\`B1:Z/I(H_P#9:S=?^_'[C98;
M_IW/[T78]!0#_D":^/\`MNO^%0ZS_GC]QHL,O^?<_O19CT1%_P"8+X@_\"4_
MQK-UG_/'[C589?R3^_\`X):3244<Z1XA'_;TO_Q50ZS_`)H_=_P#58=+[$_O
M_P""2BP@7KIGB0?2Y/\`1ZCG;^U'[O\`@%JE%?9G]_\`P0:"*/[MCXI_"9O_
M`(JB[?6'W?\``!Q2VC4^_P#X)7E!/_+EXO\`PE/^-6O6!#_PU/O*DB8ZV/C#
M\935I^<#)K^[4^\IR[!UM/%8^K__`%JU5^\#%I?RU/O,R\N[*V($_P#PD$);
MIYLP&?S6MHQG+;E^XYYSA'XN=>K,RXU*R,3^1/J7F8^7S)P1GWP*UC"2>J7W
M'/*I!KW7+[S*:ZN'!5YG8'J"QK;E2Z&'-)]2*F2>F?"3[VJ_2/\`]FKR,S^S
M\SW\EWG\OU/3J\<^A"@#E/B-_P`B7=?[Z?\`H0KMP'\='FYI_NS^1XA7T1\B
M7+?2M0NXA);V<TJ'@,B$BHE4A%V;-8T:DU>,6S9M/#DK0J+C0]5>3N8^!^JF
ML)5U?2:.F&&E;WJ<OZ^1H0^&$4@GP_K8/J'4?^R5DZ_]^)LL*O\`GU/[U_D7
MH_#T0_Y@.O?]_E_^)K-UW_/'[C585?\`/N?WHM1Z#$/^8'KP_P"WA*AUW_/'
M[C589?\`/N?WHMQ:)'_T!M>'UND_^*K-UW_-'[O^`:K#1_DG_P"!?\$LKI$"
M==*U_P#"[']'J'5;^U'[O^`:*A%?8G]__!&M8Q)]W3/$H_W;H_\`Q="F_P":
M/W?\`'32VC/[_P#@D+1,O"Z?XK'TN/\`[*J3_O0^XAIK[-3[_P#@E:2&0_\`
M+AXM_P"_]6FOYH?<9M/^6I]Y4EA8=;'Q8/K-_P#6K1-?S0^XR:?\M3[RE*A'
M6V\3#_>E_P#L:T3\X?<8M?W:GWF--J=B"RB;5@PXP]P.#^5="A/^[]QRRJT^
M\OO,<WUV>MS+_P!]FMN6/8YN>7=D<DLDN/,=FQTR<TTDMA-M[C*8@H`*`/3/
MA)][5?I'_P"S5Y&9_9^9[^2[S^7ZGIU>.?0A0!RGQ&_Y$NZ_WT_]"%=N`_CH
M\W-/]V?R/(].TN>;$LFF7EQ`P^4PJ1G\<&O<G42T4DGYGS-.C*6KBVO(VX-'
M4``>']:Q_LOC_P!DK!U?[\?Z^9TQH+_GW/\`KY%Z+1H^_AW7_P#OY_\`85FZ
MK_Y^1^XU5!?\^I_?_P``MQZ3&/\`F7]?'_;;_P"M4.J_YX_<:J@O^?4_O+4>
MF1C_`)@7B`?]O`_QJ'4?\\?N-%17_/N?W_\`!+4>GQ#_`)@GB$?]O>/_`&>L
MW4?\\?N_X!M&DOY)_?\`\$F^S1(.-(\2*?:Y)_\`9ZGF?\T?N_X!?)%?8G]_
M_!()(@?^87XI_"X/_P`55)_WH?=_P"&O[E3[_P#@E9[=?^@5XJ_[_$_UJU+^
M]#[C)Q_N5/O*LEJO_0)\4?C*?\*T4O[T/N,G#^Y4^\IRVR#_`)A7B4?5_P#[
M&M%)_P`T#)P7\E3[_P#@%&6&,9_XEVOC_>?_`.PK12?\T3)Q2^S/[_\`@'/W
MEVC2#[(]RJ8Y$LFXY_`"NB,6E[UCCG)-^[?YLI$Y.36AD%`!0`4`%`!0!Z9\
M)/O:K](__9J\C,_L_,]_)=Y_+]3TZO'/H0H`Y3XC?\B9=?[Z?^A"NW`?QT>;
MFG^[/Y'FMO91!%`TW6\8_@(Q_P"@5[#D_P":/]?,^>C!?R3_`*^1?ALXA_S"
MO$9^A_\`L*S<W_-`V5-?R3_KY%Z*SB[:3XH_!O\`[&LW-_S0-E37\E3[RW':
MH/\`F%>*O^_F*S<W_-#[C54U_)4^\LQVZ?\`0-\5C_ML1_[-6;D_YH?=_P``
MU4%_+4^__@EQ($`_X\O%`_[;G_XJLVWWA]W_``#517\M3[_^"-D1?^?;Q7_P
M&0__`!5-/S@)I=JGW_\`!*<D2_\`/IXP/TD/^-6GYP,VEVJ%22-!_P`N7C#\
M6S6B;[P,7%?RU"I)''_SZ>+!]3_]:M$WW@9.*_EJ%22&/_GV\2?\"(_^)K1-
M]X&+BNU0SKY1';2,L6KHP'#3'Y1]>*U@[O>/R,)I):*7S.=KI.0*`"@`H`*`
M"@`H`],^$GWM5^D?_LU>1F?V?F>_DN\_E^IZ=7CGT(4`<I\1O^1,NO\`?3_T
M(5VX#^.CS<T_W9_(\NT^X@FB56DU5Y0/F$#`@5[4TT_L_,^;IRBU]J_D:D?E
M?W/$G_`2/\*R=_[AT+E_OEF/RO\`GGXM_P"`D?X5F[_W#:/+VJ%R+R?^>?C+
M_OJLG?\`N&JY>U0NQ&+H(O&/YFH=_P"X;*W:H7(]G9/%H_WB:S?_`&X:JW_3
MP=(JXY;Q8/\`=S27_;@/_N(4Y1&.K>,?P!K17_N&;2_Z>%*41?W_`!D/PK17
M_N&+M_T\*D@B'\?B[_@0K17_`+AD[?\`3PJR&/LWB?\`X$!_C5J_]PR=O^GA
M3N$BDC9'_MQE/42*"#^M:Q;7\IC))Z>^<U+"\+[9(V0]0&&#BNE-/8XFFMQE
M,04`%`!0`4`%`'IGPD^]JOTC_P#9J\C,_L_,]_)=Y_+]3TZO'/H0H`Y3XC?\
MB7=?[Z?^A"NW`?QT>;FG^[/Y'BD-Q/;,3!,\1/4HQ&:^A:3W1\FI..SL;-KJ
MT"PK]HU+51+_`!>5)Q^&36$J;OI&)TPK)+WI2OY&A#JMHXRNI^(2/]EQ_P#%
M5DZ<OY8FT:T/YYEV/4K7_H)^*!]&'_Q59NG+^6!JJT/YZA<BU&U[:IXK_3_&
MH=.7\L#95H?SU"Y'J%M_T$?%1_X"#_2LW3E_+`T5:'\U3[BTE_;8Q]M\4_\`
M?K/_`++6;IR[0^__`()LJL?YJGW?\`4RQ.,KJ/BD?]L3_P#$T6:^S#[_`/@A
MS)_:J?=_P"M)*G_02\6#Z1'_``JTG_+`S;7\U3[BK)+'WU3Q9^*&K47_`"P,
MG)?SU/N*DDT/?4_%)^J?_95HHO\`E@9.4?YZGW%*6:W_`.@AXC_X$O\`]G6B
MB_Y8F3E'^:?W?\$S+J+3YWWRRZM*P&`9(E)_]"K:+FME'[SGFJ<M6Y/U7_!,
M1H9%)_=L![BM[HY;,C(P<'BF(*`"@`H`*`/3/A)][5?I'_[-7D9G]GYGOY+O
M/Y?J>G5XY]"%`&/XGT9]>T.73XYEA9V4[F&0,'-;X>JJ-13:.7%T'B*3IIV.
M$'PEN>^JQ?\`?H_XUZ?]IQ_E/&_L:?\`.ON%'PDG[ZO'_P!^3_C2_M./\OXC
M_L67\_X%RV^&VI6D?EV_B26%,YVQHP'Z-42Q\):N']?<:QRJK!6C5M_7J7$\
M#:TG3Q==CZ!O_BZS>,I?\^U_7R-%E]=?\OG_`%\RPG@[6U_YF^]_(_\`Q53]
M;I?\^D6L!77_`"^?]?,E7PGK*]?%M[_WS_\`94OK5+_GTBE@JZ_Y?,E7PQK"
M_P#,UWG_`'['^-3]9I?\^T4L'77_`"^?W(D7P[K`_P"9IN_^_2TOK%+_`)]K
M\2EA*R_Y?/[D/&@:L/\`F:+O_OS'_A4^WI_\^U^)7U:M_P`_7]R#_A']3/7Q
M-??@B#^E'MZ?_/M?B'U6K_S]?X?Y"'PW?G_F9M1_\=_PI_6(?\^U^(OJE3_G
M[+\/\B)O"VHGIXHU$?B*KZS3_P"?:(>#J_\`/Z7X$+^$-2?_`)FJ_P#Q_P#U
MU2Q=-?\`+M$O`U7_`,OI%>3P-J3_`/,U7OX@_P#Q54L937_+M$/+JK_Y?/\`
MKYF5-\*'FE:1];+NQR6>#))_[ZK99DDK*'XG/+)FW=U/P_X)`?A)+VUA/Q@/
M_P`55?VFOY?Q(_L67\_X?\$:?A+<]M6B_P"_1_QI_P!IQ_E%_8T_YU]PT_"6
M\[:G!_WP:/[2A_*+^QJG\Z&_\*FOO^@E;_\`?+4_[2A_*Q?V-4_F1U?@OPE<
M>%VO#/<QS"<+C8",8SZ_6N+%XF->UE:QZ6`P4L+S<SO<ZRN$],*`$)`ZG%`"
M@YZ4`%`!0`F1ZB@`R/44`*"#TH`3</44`&1ZB@`W#U%`"T`%`";AZB@!0<]*
M`"@!`0<X(..M`"T`)D#N*`#</44`+0`4`%`!0!7N["UOD"W,*R``@9ZCZ4;!
M8X[PQ>2:?JYM)F/D78/EDGN"0/Y$?E5,A:'<U)9A^)[J2/3FM;<XFF1F)_NH
MHRQ_I^--"96\'V5N=)BO#&&N"S?.>2.W%#%$C\5:(CV;WUHFR:,[I`O\0[GZ
MTTP:-3P]/:W&D12VL2Q`\.J]F'6DQHS7TFTU/Q$X2$+;6PQ-M)'F.><?A3O9
M"M=FY/IMG/:"VD@4Q*#M'3;]*D=CE?".GVM[%>&ZA$I1PH+=AS5,F*)-;23P
MS=VUW82NMO(VUX2Q*_K0M1O0ZX%98@2,JZ]#Z&I*.*UC3;:+Q78VT:;()]I=
M%.`>2#_*J3T(:U.T@MXK:(101K&@Z*M26%Q.EM;R3R'"1J6/T%`'+>&K^X76
MKVTO`5DG_?`'L<9Q^1'Y53)6YUM24<SXQLX!I;7BQA;@.HWCJ1TYJD3(LZ5H
MVG3:1:R26B,[Q*68YR3BDV-)"7VC2V4+7.D7$L,L8W>27+(_M@T)A:VQ9T#6
M5UBQ,A4)-&=LBCU]10U8$[FK2&%`",<(3Z"@#B;VQ:7PC8W\/$UL2^1UVEC_
M`"X-5U(Z'5:3?KJ6F0W0(RR_,/1AUI/0I:F2_P#IMCJ^IM]UX7B@_P!Q0>?Q
M.:-A>9)X./\`Q3T8]';^=#W".QO$!E*D9!X(-(HXE9)_"^MW%G#&9(;H9@7T
M8_=_7BJW(V9UNG68L+)(<[G^\[?WF/)/YU):T+)Z&@#BO">H06,-]YWF??!R
ML;-CKZ"J9"T+D@3Q=>Q>4VW3[5LL3]YR?;L/_KT;#W.J````X`J2CD];_P"1
MTTKZ+_Z$:I;$O<ZRI*,;79XRUI822+&MQ)F0LP`V+R?SX%-"9B>(KBWM=:L-
M5M9XI"IVR!'!.!]/8D4UV$][G9(ZR(KJ<JPR#[5)1A>,O^1>D_WU_G36XI;&
MCHO_`"!++_KBO\J&"+U(9Q?A(>7X@U.-/]6-WZ-Q5/8E;G:5)04`0W3^79SN
M?X8V/Z4`4-#B23PW:Q.,HT6TCU!IO<2V.6L7N],O;[0(PQ:=ML;?W0>K?]\_
MRI^9.VAUU]!';:!<P1C;'';LJCV"TBNAG>##G0![2M_2A[BCL=#2*.1\3''B
M31_]]?\`T(52V)>YUU24(>AH`Y3P.?W-_P#]=!_6J9,2"\#>%_$2W<:G[!='
M#J.WJ/PZBC=!LSL8Y$FB62-@R,,J1T(J2CE-;(_X332A[+_Z$:I;$O<ZVI*,
M&RAAU;5KZ\GB26&(B"(.N1QRQY]Z>PMR36=#M+C2;A(+2*.8+N0H@!R.<<4)
M@T,\)7_VS1$1CF2W/EGZ=OT_E0]`6PWQE_R+TG^^O\Z%N$MC1T7_`)`EE_UQ
M7^5#!":MJ<6EV3RN09",1IW9NU"5P;L9GAG37TNPGO+L$3S?.P[JHY_.AB2L
M2&_N6N(T:0I+*J,BJ1@!B0.,9.,<\T#->SN/M5JDI7:QR&'H0<']0:0R#4-.
M;4$,9NYHHF7:R1X&?TS3V%89INE?V8BQQWD\D*@XC?!`_3-%P2L6#86YU$7^
MS_2`GE[O:D.Q'J&GG4(C";J6*-AAECQ\P]\BGL*Q6TS0DTHXMKR?RL[C&VTJ
M3^5%[@E8U6!*D`X..H[4AF%=^%XKVX6XN+ZZ>5?NME1M^G'%.]A6->U@DMXR
MKW$DY[%\9'Y"D,;>6KW47EK<RP#N8\9/YB@#-T_PW%I<I>UO;A-V-R_*0V/7
MBG<25C3O+*"_MFM[F,/&W;T]Q2V&5=-TDZ8C0PW<K0$':C@'8?4&G<25BG/X
M7BNKQ;N:^NFG7&U\J-N.F.*+A8TI+*62T$!OIP>\B[0Q'ITI`0Z9HZZ4-D-U
M,T62?+?!&?7IFFV"5B[<1/-"429X3_>3&?UI#,FP\-1:;.9;:]N4+?>&5(;Z
M\4[B2L3:GH:ZK\MQ>3B+.1&N``?RH3L#5QEMH)M85ABU.\6)>BAEX^G%%PL6
MK;2+.VF\_8TL_P#SUE8NWZ]*+A8NLH92K#((P12&9#:1*)!M=&VA5CD9B&C"
=GY>,<D9/<9[T[BL:=O`MM;I"F2%'4]2>YI#/_]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
